Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.
Dr. Petros Grivas
Advertisement
Dr. Petros Grivas is the clinical director of the Genitourinary Cancers Program and a professor in the Clinical Research Division at Fred Hutch Cancer Center, in Seattle; he also serves as a professor in the Division of Hematology and Oncology, at the University of Washington School of Medicine.
Articles by Dr. Petros Grivas
Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the JAVELIN Bladder 100 trial.
Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three practice-changing phase 3 trials.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
SUNRiSE-1 Participant Shares Insights on Bladder Cancer Education
2
Fertility Preservation During Breast Cancer: ‘I Would Do It All Again’
3
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
4
What Are My Options for Liver Cancer Treatment?
5
